

Remarks

Support for Amendments:

Claims 37 and 39 are amended herein to add "and" between the next to last compound and last compound claimed in said claims and to change "and" to "or" before the clause "pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof".

Claim 40-42, and 44 are amended to change "and" to "or" before the clause "pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof".

Claims 47-51 are amended to include "or the (R) or (S) enantiomer thereof, or the *cis* or *trans* isomer thereof, or a pharmaceutically acceptable salt thereof, or solvate of the compound or salt thereof" referring to the compounds of the claim referenced within said claim amended.

The amendments to claims 37, 39, 40-42, and 44 are purely grammatical.

The amendments to claims 47-51 are support by at least page 6, lines 20 to 35.

The amendments do not add new subject matter.

Conclusion

Applicants believe that the amendments are supported by the application and do not add new subject matter. Applicants believe that the claims are in order for allowance, early notice of which is requested. If Examiner has any questions concerning this request, Examiner is invited to contact the below-signed attorney. It is believed that no fee is due; however, please charge any required fee payment or credit any overpayment to Charge Account 16-1445.

Respectfully submitted,

/Mary J. Hosley/

Mary J. Hosley, Attorney, Registration No. 48,324

Date: 8 March 2007

Pfizer, Inc
150 East 42nd Street, Floor 5
New York, NY 10017-5612
Telephone No. 212.733-0460
Telefax No. 212.573-1939